{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:15:57Z","timestamp":1784139357060,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T00:00:00Z","timestamp":1476662400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1007\/s40618-016-0557-y","type":"journal-article","created":{"date-parts":[[2016,10,17]],"date-time":"2016-10-17T11:37:39Z","timestamp":1476704259000},"page":"275-279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effects of daily tadalafil on lower urinary tract symptoms in young men with multiple sclerosis and erectile dysfunction: a pilot study"],"prefix":"10.1007","volume":"40","author":[{"given":"D.","family":"Francomano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ilacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tartaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Inghilleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Aversa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,17]]},"reference":[{"key":"557_CR1","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/9781439805046-27","volume-title":"Textbook of the neurogenic bladder","author":"L Leboeuf","year":"2008","unstructured":"Leboeuf L, Cohen B, Gousse AE (2008) Multiple sclerosis. In: Corcos J, Schick E (eds) Textbook of the neurogenic bladder. CRC Press, Boca Raton, pp 294\u2013311"},{"key":"557_CR2","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2990.1978.tb00555.x","volume":"4","author":"DR Oppenheimer","year":"1978","unstructured":"Oppenheimer DR (1978) The cervical cord in multiple sclerosis. Neuropathol Appl Neurobiol 4:151\u2013162","journal-title":"Neuropathol Appl Neurobiol"},{"key":"557_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/PL00007835","volume":"249","author":"O Fernandez","year":"2002","unstructured":"Fernandez O (2002) Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis. J Neurol 249:1\u20138","journal-title":"J Neurol"},{"key":"557_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00192-006-0131-9","volume":"18","author":"G Quarto","year":"2007","unstructured":"Quarto G, Autorino R, Gallo A et al (2007) Quality of life in women with multiple sclerosis and overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 18:189\u2013194","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"557_CR5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/377150a0","volume":"377","author":"GC Ebers","year":"1995","unstructured":"Ebers GC, Sadovnick AD, Risch NJ (1995) A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 377:150\u2013151","journal-title":"Nature"},{"key":"557_CR6","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1002\/ana.410360805","volume":"36","author":"CM Poser","year":"1994","unstructured":"Poser CM (1994) The epidemiology of multiple sclerosis: a general overview. Ann Neurol 36:S180\u2013S193","journal-title":"Ann Neurol"},{"key":"557_CR7","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.juro.2009.12.060","volume":"183","author":"A Kanai","year":"2010","unstructured":"Kanai A, Andersson KE (2010) Bladder afferent signaling: recent findings. J Urol 183:1288\u20131295","journal-title":"J Urol"},{"key":"557_CR8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.eururo.2010.11.040","volume":"59","author":"KE Andersson","year":"2011","unstructured":"Andersson KE (2011) Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 59:377\u2013386","journal-title":"Eur Urol"},{"key":"557_CR9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.eururo.2014.08.072","volume":"67","author":"CR Chapple","year":"2015","unstructured":"Chapple CR, Roehrborn CG, McVary K et al (2015) Effect of tadalafil on male lower urinary tract symptoms: an integrated analysis of storage and voiding international prostate symptom subscores from four randomised controlled trials. Eur Urol 67:114\u2013122","journal-title":"Eur Urol"},{"key":"557_CR10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s40618-015-0339-y","volume":"39","author":"R Pofi","year":"2016","unstructured":"Pofi R, Gianfrilli D, Badagliacca R et al (2016) Everything you ever wanted to know about phosphodiesterase 5 inhibitors and the heart (but never dared ask): How do they work? J Endocrinol Invest 39:131\u2013142","journal-title":"J Endocrinol Invest"},{"key":"557_CR11","doi-asserted-by":"crossref","first-page":"182","DOI":"10.7224\/1537-2073.2012-049","volume":"15","author":"J Burks","year":"2013","unstructured":"Burks J, Chancellor M, Bates D et al (2013) Development and validation of the actionable bladder symptom screening tool for multiple sclerosis patients. Int J MS Care Winter 15:182\u2013192","journal-title":"Int J MS Care Winter"},{"key":"557_CR12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1007\/BF03347112","volume":"36","author":"A Radicioni","year":"2013","unstructured":"Radicioni A, Lenzi A, Spaziani M et al (2013) A multicenter evaluation of immunoassays for follicle-stimulating hormone, luteinizing hormone and testosterone: concordance, imprecision and reference values. J Endocrinol Invest 36:739\u2013744","journal-title":"J Endocrinol Invest"},{"key":"557_CR13","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ejpain.2008.05.014","volume":"13","author":"A Conte","year":"2009","unstructured":"Conte A, Bettolo CM, Onesti E et al (2009) Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis. Eur J Pain 13:472\u2013477","journal-title":"Eur J Pain"},{"key":"557_CR14","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1111\/j.1743-6109.2010.01797.x","volume":"7","author":"G Lombardi","year":"2010","unstructured":"Lombardi G, Macchiarella A, Del Popolo G (2010) Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med 7:2192\u20132200","journal-title":"J Sex Med"},{"key":"557_CR15","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.2013.799665","volume":"14","author":"R Bruzziches","year":"2013","unstructured":"Bruzziches R, Francomano D, Gareri P et al (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14:1333\u20131344","journal-title":"Expert Opin Pharmacother"},{"key":"557_CR16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-3-642-17969-3_13","volume":"204","author":"S Uckert","year":"2011","unstructured":"Uckert S, Stief CG (2011) Treatment of erectile dysfunction and lower urinary tract symptoms by phosphodiesterase inhibitors. Handb Exp Pharmacol 204:307\u2013322","journal-title":"Handb Exp Pharmacol"},{"key":"557_CR17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/nau.20485","volume":"26","author":"KE Andersson","year":"2007","unstructured":"Andersson KE, Uckert S, Stief C et al (2007) Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26:928\u2013933","journal-title":"Neurourol Urodyn"},{"key":"557_CR18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1152\/jn.2001.86.1.304","volume":"86","author":"N Yoshimura","year":"2001","unstructured":"Yoshimura N, Skei S, de Groat WC (2001) Nitric oxide modulates Ca(2+) channels in dorsal root ganglion neurons innervating rat urinary bladder. J Neurophysiol 86:304\u2013311","journal-title":"J Neurophysiol"},{"key":"557_CR19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.eururo.2010.07.026","volume":"58","author":"R Caremel","year":"2010","unstructured":"Caremel R, Oger-Roussel S, Behr-Roussel D et al (2010) Nitric oxide\/cyclic guanosine monophosphate signaling mediates an inhibitory action on sensory pathways of the micturition reflex in the rat. Eur Urol 58:616\u2013625","journal-title":"Eur Urol"},{"key":"557_CR20","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/j.1476-5381.1992.tb14483.x","volume":"107","author":"K Persson","year":"1992","unstructured":"Persson K, Igawa Y, Mattiasson A et al (1992) Effects of inhibition of the l-arginine\/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br J Pharmacol 107:178\u2013184","journal-title":"Br J Pharmacol"},{"key":"557_CR21","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.urology.2007.12.002","volume":"72","author":"K Sesatomi","year":"2008","unstructured":"Sesatomi K, Hiragata S, Miyazato M et al (2008) Nitric oxide-mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology 72:696\u2013700","journal-title":"Urology"},{"key":"557_CR22","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00207.2009","volume":"297","author":"DE Artim","year":"2009","unstructured":"Artim DE, Kullman FA, Daughtery SL et al (2009) Activation of the nitric oxide-cGMP pathway reduces phasic contractions in neonatal rat bladder strips via protein kinase G. Am J Physiol Renal Physiol 297:F333\u2013F340","journal-title":"Am J Physiol Renal Physiol"},{"key":"557_CR23","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/nau.21246","volume":"31","author":"A Kanai","year":"2012","unstructured":"Kanai A, Zabbarova I, Oefelein M et al (2012) Mechanisms of action of botulinum neurotoxins, b3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn 31:300\u2013308","journal-title":"Neurourol Urodyn"},{"key":"557_CR24","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.expneurol.2009.07.016","volume":"219","author":"A Sculptoreanu","year":"2009","unstructured":"Sculptoreanu A, Artim DE, de Groat WC (2009) Neurokinins inhibit low threshold inactivating K+ currents in capsaicin responsive DRG neurons. Exp Neurol 219:562\u2013573","journal-title":"Exp Neurol"},{"key":"557_CR25","doi-asserted-by":"crossref","first-page":"E259","DOI":"10.1111\/j.1464-410X.2012.11255.x","volume":"110","author":"T Minegawa","year":"2012","unstructured":"Minegawa T, Aizawa N, Igawa Y et al (2012) Inhibitory effects of phosphodiesterase 5 inhibitor, tadalafil, on mechanosensitive bladder afferent nerve activities of the rat and on acrolien-induced hyperactivity of these nerves. BJU Int 110:E259\u2013E266","journal-title":"BJU Int"},{"key":"557_CR26","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.eururo.2010.10.035","volume":"59","author":"N Aizawa","year":"2011","unstructured":"Aizawa N, Igawa Y, Nishizawa O et al (2011) Effects of nitric oxide on the primary bladder afferent activities of the rat with and without intravesical acrolein treatment. Eur Urol 59:264\u2013271","journal-title":"Eur Urol"},{"key":"557_CR27","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1111\/j.1743-6109.2012.02946.x","volume":"9","author":"L Vignozzi","year":"2012","unstructured":"Vignozzi L, Filippi S, Morelli A et al (2012) Testosterone\/estradiol ratio regulates NO-induced bladder relaxation and responsiveness to PDE5 inhibitors. J Sex Med 9:3028\u20133040","journal-title":"J Sex Med"},{"key":"557_CR28","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1743-6109.2006.00264.x","volume":"3","author":"EA Greco","year":"2006","unstructured":"Greco EA, Pili M, Bruzziches R et al (2006) Testosterone:estradiol ratio changes associated with long-term tadalafil administration: a pilot study. J Sex Med 3:716\u2013722","journal-title":"J Sex Med"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-016-0557-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0557-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T17:46:50Z","timestamp":1568483210000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-016-0557-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,17]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["557"],"URL":"https:\/\/doi.org\/10.1007\/s40618-016-0557-y","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,17]]}}}